, by Day 14, 62 percent of patients treated early were able to be discharged from the hospital, compared with 49 percent of patients who were treated late.Gilead's Remdesivir:
First trials in China show "was not associated with clinical or virological benefits." 14% of treated patients vs 13% of control arm died after a month.
A month later new results with a median recovery time of 11 days compared to 15 days for those who took the placebo. A mortality rate of 8% in the remdesivir group versus 11.6% of patients in the control group who died. Sorry but that is unimpressive.
The treated group showed an improvement in the time to recovery of 15 days in the placebo group to 11 days in the treated group, and early treatment show an advantage, to quote the company ", by Day 14, 62 percent of patients treated early were able to be discharged from the hospital, compared with 49 percent of patients who were treated late". Seriously? That is so tremendously unimpressive and of little consequence to the 8% who still die.
So a less than 4% improvement in mortality and....adverse effects? "10 percent of patients in either group were nausea (5-day: 10.0%, n=20/200 vs. 10-day: 8.6%, n=17/197) and acute respiratory failure (5-day: 6.0%, n=12/200 vs. 10-day: 10.7%, n= 21/197). Grade 3 or higher liver enzyme (ALT) elevations occurred in 7.3 percent (n=28/385) of patients, with 3.0 percent (n=12/397) of patients discontinuing remdesivir treatment due to elevated liver tests".
Seriously?
Gilead's treatment is crap. Its the US prerogative I hear you say? No, in Australia our muppet authorities are ordering the drug for 5 hospitals in Australia.
This pandemic is becoming more about political mismanagement rather than the virus itself.
- Forums
- ASX - By Stock
- MSB
- Gilead vs Mesoblast
Gilead vs Mesoblast, page-269
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B |
Open | High | Low | Value | Volume |
98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 71720 | 94.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 10463 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 71720 | 0.940 |
7 | 80257 | 0.935 |
5 | 107550 | 0.930 |
6 | 117669 | 0.925 |
6 | 104084 | 0.920 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 10463 | 1 |
0.950 | 71797 | 3 |
0.955 | 114621 | 4 |
0.960 | 52017 | 4 |
0.965 | 44050 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |